November 18, 2016 06:59 AM EST
Bioregnum
Opinion

Gilead needs to stop wait­ing and start buy­ing; Let's em­brace Chi­na as a new bio­phar­ma pow­er

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

#JPM25 live blog day 3: Zealand aims to part­ner with a top-10 phar­ma; Lil­ly's 'pru­den­t' deal­mak­ing plans

On­col­o­gy biotech plots ex­pe­dit­ed ap­proval for bone can­cer drug af­ter Phase 2 win

BIO CEO plans to join FDA mod­ern­iza­tion ad­vi­so­ry board un­der Trump ad­min­is­tra­tion

HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

Hinge Bio's $30M raise; Keros re­ports ad­di­tion­al is­sues in Phase 2 PAH tri­al

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

A service from the Financial Times